Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.76 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.58 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947863 | 0.94 | FFAR1 (0.67) | FFAR1CYSLTR2CYSLTR1S1PR1PPARG | |
| SCHEMBL17413767 | 0.94 | FFAR1 (0.71) | FFAR1CYSLTR2CYSLTR1S1PR1FFAR4 | |
| SCHEMBL17413763 | 0.93 | FFAR1 (0.69) | FFAR1CYSLTR2CYSLTR1S1PR1FFAR4 | |
| SCHEMBL1746597 | 0.86 | FFAR1 (1.00) | FFAR1S1PR1FFAR4S1PR3S1PR5 | |
| SCHEMBL17345292 | 0.86 | PPARA (0.69) | FFAR1CYSLTR2CYSLTR1PPARGPPARA | |
| SCHEMBL25456542 | 0.86 | PPARA (0.69) | FFAR1CYSLTR2CYSLTR1PPARGPPARA | |
| SCHEMBL1206101 | 0.85 | PPARA (0.64) | FFAR1PPARGPPARA | |
| SCHEMBL1746650 | 0.85 | FFAR1 (0.88) | FFAR1FFAR4 | |
| SCHEMBL4656572 | 0.85 | FFAR1 (0.97) | FFAR1S1PR1FFAR4S1PR3S1PR5 | |
| SCHEMBL1206748 | 0.84 | LMNA (0.68) | FFAR1FFAR4PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | FFAR1 61/4885CYSLTR2 119/4885CYSLTR1 115/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | FFAR1 56/4885CYSLTR2 129/4885CYSLTR1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.